AVENIO ctDNA Expanded Kit V2

Overview

The AVENIO ctDNA Expanded Kit V2 is a next-generation sequencing (NGS) liquid biopsy assay with a 77 gene panel containing genes in U.S. National Comprehensive Cancer Network (NCCN) Guidelines¹ and emerging cancer biomarkers. It is a pan-cancer assay that’s specially optimized for lung cancer and colorectal cancer (CRC) research.

Features and Benefits

• Contains genes in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines¹ and emerging cancer biomarkers
• All four mutation classes (SNVs, indels, fusions and CNVs) in a single assay
• Exceptional analytical performance supported by integrated digital error suppression (iDES) strategies combining molecular barcodes with in silico error suppression techniques^2,3
• Includes reagents, bioinformatics and software
• Streamlined, end-to-end workflow from extraction to analysis and reporting in five days

Exceptional Performance³

The AVENIO ctDNA Expanded Kit V2 is one of three assays in the AVENIO ctDNA research assay portfolio. Learn more about the 17-gene AVENIO ctDNA Targeted Kit V2 for guideline-driven tumor profiling or the 197-gene AVENIO ctDNA Surveillance Kit V2 for longitudinal tumor burden monitoring.